Business Context and Reporting Period
This Form 8-K was filed by Nile Therapeutics, Inc. (not Capricor Therapeutics, Inc.) on April 2, 2012, reporting events occurring on March 30, 2012. The filing details the entry into material definitive agreements for a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Offering Size: 3,350,000 shares of common stock.
- Price Per Share: $0.40.
- Warrants Issued: 2,512,500 warrants (0.75 warrant per share) with an exercise price of $0.50 per share.
- Gross Proceeds: $1.34 million.
- Estimated Expenses: Approximately $0.2 million (selling commissions and expenses).
- Placement Agent Fee: 7% of gross proceeds ($93,800) plus a $35,000 non-accountable expense allowance.
- Insider Participation: Executive Chairman, CEO, CFO, and Executive VP collectively subscribed to 275,000 shares for $110,000.
Material Changes and Agreements
The Company entered into Subscription Agreements to sell the shares and warrants described above. The closing is expected on or around April 4, 2012. The offering was conducted pursuant to a shelf registration statement (Form S-3) effective since March 12, 2010. The filing does not provide comparative financial data (revenue, profit, cash flow) as this is a current report regarding a specific transaction rather than a periodic financial report.
Outlook, Risks, and Contingencies
- Registration Obligation: The Company must file an Additional Registration Statement within 15 business days of closing and have it declared effective within 90 days.
- Liquidated Damages: If the Additional Registration Statement is not effective within 90 days, the Company must pay purchasers 1% of their investment for each 30-day period of delay, capped at 12% of the investment.
- Warrant Exercise Period: Warrants are exercisable for five years beginning on the earlier of the effectiveness of the Additional Registration Statement or one year and one day after issuance.
Investor Verification Checklist
- Verify the closing date of the offering (expected April 4, 2012) and actual net proceeds received.
- Confirm the filing and effectiveness date of the Additional Registration Statement to assess potential liquidated damages.
- Review the impact of the 3,350,000 new shares and 2,512,500 potential warrant shares on existing shareholder dilution.
- Check subsequent filings for updates on the Company's cash position and burn rate following this capital raise.